EFL

Role: Mentor

Tracks: Life Sciences - Digital Health

Ron Lennox

Life Sciences Investor, Board Member, Founder

Ron has been an active investor in early stage life sciences companies for over twenty years. He has served on the boards of over 18 companies including General Surgical Innovations, Inc. (acquired by Tyco International Corp.), GeneOhm Sciences, Inc. (acquired by Becton Dickinson, Inc.) and Applied Molecular Evolution, Inc. (acquired by Eli Lilly Corp.). He has been involved in the founding of seven companies, six of which were successful. He was the founding CEO and Chairman of Protometrix, Inc. (acquired by Life Technologies, Inc.) and also of CGI Pharmaceuticals, Inc. (acquired by Gilead Sciences, Inc.). In addition, he was founding Chairman of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and a founder who served as Executive Chairman of Bikam Pharmaceuticals, Inc., engineering the sale of the company to Shire Pharmaceuticals PLC in July 2014. He has also helped found polyGenomics, Inc., American Renal Associates, Inc., and Biorelix, Inc. 11 additional companies he led investments in had successful IPOs, including i-STAT Corp, British Biotechnology, Ltd and Threshold Pharmaceuticals, Inc. Ron began his venture capital career with Hancock Venture Partners (now HarbourVest Partners). He was a Founding Partner at CHL Medical Partners which raised three successive funds from institutional investors. He is a Mount Sinai Innovation Partner and serves on the board of Octagon Therapeutics, Inc., and is an advisor to several privately held biotechnology companies. Ron has a B.Sc. in Molecular Biology from the University of Glasgow, a D.Phil. in Cell Biology from Oxford University and an MBA from The Wharton School of the University of Pennsylvania. He lives in New York’s Greenwich Village with his wife and daughter.